Agios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.09), Briefing.com reports. The business had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 44.84% and a negative net margin of 1,165.69%. Agios Pharmaceuticals’s revenue was up 28.4% compared to the same quarter last year. During the same quarter last year, the company earned ($1.51) EPS.

Agios Pharmaceuticals Trading Down 1.2 %

NASDAQ:AGIO traded down $0.54 during trading hours on Friday, reaching $43.96. 563,979 shares of the company’s stock were exchanged, compared to its average volume of 595,648. Agios Pharmaceuticals has a 12 month low of $19.80 and a 12 month high of $50.35. The business’s 50-day simple moving average is $44.48 and its two-hundred day simple moving average is $34.47.

Analysts Set New Price Targets

Several research firms recently weighed in on AGIO. The Goldman Sachs Group increased their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. Royal Bank of Canada increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $55.00 and gave the company an “outperform” rating in a report on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Agios Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $51.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.